Form 4: Oramed Pharmaceuticals CFO Avraham Gabay Reports Acquisition of Common Stock

Avraham Gabay, CFO of Oramed Pharmaceuticals, reports the acquisition of 76,000 shares of common stock through the settlement of performance stock units (PSUs).

Summary

• On February 11, 2025, Avraham Gabay, the Chief Financial Officer of Oramed Pharmaceuticals Inc., acquired a total of 76,000 shares of common stock.
• 34,000 shares were acquired through the settlement of performance stock units (PSUs) granted on June 20, 2024, which vested on February 11, 2025, upon achievement of performance criteria.
• An additional 42,000 shares were acquired through the settlement of PSUs granted on January 2, 2025, which also vested on February 11, 2025, based on the achievement of performance criteria.
• Following these transactions, Gabay directly owns 434,040 shares of Oramed Pharmaceuticals Inc. common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by the CFO suggests confidence, but it's a routine transaction related to previously granted PSUs.

Positives

• The acquisition of shares by a key executive could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Executive stock ownership is a common practice in publicly traded companies and is often used to align the interests of management with those of shareholders.

Stakeholder Impact

• The increased ownership of company stock by a key executive could positively influence investor sentiment.

Key Dates

Keywords

Oramed Pharmaceuticals, Avraham Gabay, CFO, Common Stock, Performance Stock Units, PSUs, Beneficial Ownership, Form 4